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Glutathione S-transferases (GSTs) detoxify potentially mutagenic
and toxic DNA-reactive electrophiles, including metabolites of
several chemotherapeutic agents, some of which are suspected
human carcinogens. Functional polymorphisms exist in at least
three genes that encode GSTs, including GSTM1, GSTT1, and
GSTP1. We hypothesize, therefore, that polymorphisms in genes
that encode GSTs alter susceptibility to chemotherapy-induced
carcinogenesis, specifically to therapy-related acute myeloid leu-
kemia (t-AML), a devastating complication of long-term cancer
survival. Elucidation of genetic determinants may help to identify
individuals at increased risk of developing t-AML. To this end, we
have examined 89 cases of t-AML, 420 cases of de novo AML, and
1,022 controls for polymorphisms in GSTM1, GSTT1, and GSTP1.
Gene deletion of GSTM1 or GSTT1 was not specifically associated
with susceptibility to t-AML. Individuals with at least one GSTP1
codon 105 Val allele were significantly over-represented in t-AML
cases compared with de novo AML cases [odds ratio (OR), 1.81; 95%
confidence interval (CI), 1.11–2.94]. Moreover, relative to de novo
AML, the GSTP1 codon 105 Val allele occurred more often among
t-AML patients with prior exposure to chemotherapy (OR, 2.66;
95% CI, 1.39–5.09), particularly among those with prior exposure
to known GSTP1 substrates (OR, 4.34; 95% CI, 1.43–13.20), and not
among those t-AML patients with prior exposure to radiotherapy
alone (OR,1.01; 95% CI, 0.50–2.07). These data suggest that inher-
itance of at least one Val allele at GSTP1 codon 105 confers a
significantly increased risk of developing t-AML after cytotoxic
chemotherapy, but not after radiotherapy.
Extensive use of combination chemotherapy and radiationtherapy has resulted in increased long-term survival of
cancer patients. A life-threatening complication of improved
long-term cancer survival is an increased risk of developing a
second therapy-related cancer, of which acute myeloid leukemia
(AML) is the most common (1–6). The cumulative risk of
therapy-related AML (t-AML) at 10 years after treatment for
breast cancer, non-Hodgkin’s lymphoma, ovarian cancer, or
Hodgkin’s disease has been estimated at 1.5%, 7.9%, 8.5%, and
3.8%, respectively (7–10).
The cytogenetic and clinical presentation of t-AML differs
according to the nature of the primary therapy, suggesting the
existence of multiple genetic mechanisms by which t-AML may
develop (11). Recent efforts have concentrated on elucidating
genetic factors that modulate susceptibility to t-AML. Indeed,
germ-line mutations in the tumor suppressor gene p53 have been
associated with increased susceptibility to t-AML (12, 13), as has
polymorphic variation in the NAD(P)H:quinone oxidoreductase
gene (14, 15) and the cytochrome P450 3A4 gene (16).
Polymorphisms of functional significance have also been
reported in genes that encode phase II metabolizing enzymes,
including glutathione S-transferases (GSTs). GSTs detoxify po-
tentially mutagenic and cytotoxic DNA-reactive metabolites by
conjugation to glutathione. There are four cytosolic families of
GSTs, including GST a, GST m, GST u, and GST p (17). Gene
clusters of GST m (GSTM1, M2, M3, M4, and M5) and GST u
(GSTT1 and T2) are located on chromosomes 1 and 22, respec-
tively (18, 19). Independent gene deletions exist at both GSTM1
and GSTT1 loci, resulting in a lack of active protein in ’50% and
20% of Caucasians, respectively (20, 21). GST p or GSTP1,
encoded by a single locus (GSTP1) on chromosome 11, is also
subject to polymorphic variation (22). Codon 105 residue forms
part of the GSTP1 active site for binding of hydrophobic
electrophiles (23), and the Ile–Val substitution affects substrate-
specific catalytic activity and thermal stability of the encoded
protein (24–27).
Polymorphisms within genes that encode GSTs have been
associated with susceptibility to nonmalignant (28) and malig-
nant human diseases (29, 30), including AML (31). Presumably,
altered cancer risk because of polymorphic variation is mediated
by differential ability to conjugate and detoxify both endoge-
nously formed and exogenously derived electrophiles and their
metabolites. GSTs, particularly GSTP1, also conjugate and
protect against the cytotoxic effects of some chemotherapeutic
agents. Reactive metabolites of ifosfamide, busulfan, and
chlorambucil are substrates for GSTP1-mediated glutathione
conjugation in vitro (27, 32, 33). Furthermore, transfection of
GSTP1 gene or antisense expression vectors demonstrates a role
in cellular resistance to platinum derivatives, etoposide, cyclo-
phosphamide, melphalan, and adriamycin (34–40).
Several chemotherapeutic agents, including cyclophospha-
mide, melphalan, adriamycin, and chlorambucil, are suspected
human leukemogens. Furthermore, CD341 bone marrow stem
cells, the target cell population for leukemic transformation, can
be protected against the cytotoxic effects of these suspected
leukemogens by GSTP1-gene transduction (37–39). These ob-
servations led us to question whether GSTs may also protect
bone marrow stem cells against chemotherapy-induced mu-
tagenesis and leukemogenesis. Thus, we hypothesize that poly-
morphic variation in genes encoding GSTs may alter suscepti-
bility to t-AML. To begin to test this hypothesis, we established
a rare-case series of individuals with AML whose leukemia
developed subsequent to cytotoxic therapy for a previous con-
dition, and we examined this population for the distribution of
polymorphisms in GSTM1, GSTT1, and GSTP1.
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Materials and Methods
Subjects. Polymorphisms of three groups of subjects were com-
pared; there were 89 cases of t-AML, 420 cases of de novo AML,
and 1,022 unaffected controls. For this study, t-AML is defined
as AML following chemotherapy andyor radiotherapy diag-
nosed at least 2 months after the start of the initial cytotoxic
therapy. All samples from the de novo AML and control groups,
and 24 of those with t-AML, were routinely obtained as part of
a large, population-based, case-control study of acute leukemia
that has been fully described elsewhere (31, 41–44). Briefly, all
subjects were between 16 and 69 years of age and were diagnosed
with AML between April 1991 and December 1996 while
resident in parts of the north and southwest of England. All
diagnoses were pathologically confirmed. Individuals were con-
sidered ineligible if, before a diagnosis of acute leukemia, they
had been diagnosed with chronic myeloid leukemia or myelo-
dysplastic syndrome within the previous 6 months, or with any
malignancy within the previous 2 years. Two controls per patient,
individually matched by sex, age, and ethnic origin, were ran-
domly selected from the general practice where the case was
registered.
Additional DNA samples were obtained from 65 subjects with
t-AML enrolled in the Medical Research Council (MRC) of the
United Kingdom’s AML trials 10, 11, or 12 (45). To treat these
65 individuals in a similar manner to those enrolled in the
case-control study, each person was individually matched by sex
and age (63 years, or the nearest age for MRC trial patients over
70 years old) to one of the unused pool of unaffected controls
recruited in the main case-control study. However, an un-
matched statistical analysis was used in all instances (see below).
DNA Extraction. DNA was extracted either from whole frozen
blood (case-control study) or from archived bone marrow smears
(MRC cases). Genomic DNA was extracted from whole frozen
blood, as previously described (31), and from bone marrow
smears by using the Qiamp DNA-extraction minikit (Qiagen,
Hilden, Germany) according to the manufacturer’s recommen-
dations for archived bone marrow.
GST Genotyping. GSTM1 and GSTT1 genotyping was performed
by using a multiplex PCR assay as previously described (28).
Briefly, the presence of 215-bp and 480-bp amplicons corre-
sponds to individuals with at least one intact GSTM1 and GSTT1
allele, respectively. The absence of either of these amplicons
corresponds to individuals homozygous for the null allele. The
presence of a 268-bp amplicon from the ubiquitous b-globin
gene acts as an internal control, confirming successful PCR
amplification.
GSTP1 codon 105 genotyping was performed by using a
PCR-restriction fragment length polymorphism assay as previ-
ously described (28). Briefly, digestion of a 177-bp amplicon with
BsmA1 that results in either retention of the 177-bp amplicon or
in complete digestion to 93-bp and 84-bp fragments corresponds
to individuals homozygous for the Ile or Val alleles, respectively.
The presence of all three fragments after digestion corresponds
to individuals heterozygous at codon 105.
Statistical Analysis. Odds ratios (ORs) and 95% confidence in-
tervals (CIs), adjusted for age and sex, were estimated by using
unconditional logistic regression (46). GSTP1 was analyzed as a
trichotamous (IleyIle, IleyVal, ValyVal) or dichotomous (Iley
Ile, IleyVal 1 ValyVal) variable. Chemotherapy was given
precedence over radiotherapy; individuals who received both
were grouped with those who received chemotherapy alone.
Confirmed GSTP1 substrates include the following chemother-
apeutic agents wherein GSTP1-catalyzed in vitro glutathione
conjugation has been demonstrated or where sense or antisense
gene expression confers resistance or sensitivity, respectively:
chlorambucil (27); busulfan (33); ifosfamide (32); adriamycin
(35–38, 40); etoposide (36, 38, 40); cyclophosphamide (37, 39);
melphalan (36, 38); and cisplatin derivatives (34, 36, 38). All
analyses were conducted by using STATA 1999 (Stata, College
Station, TX).
Results
Descriptive Results. Table 1 describes the distribution of the
t-AML case series, the de novo AML cases, and the controls
by sex, age, French–American–British (FAB) acute leukemia
classification type, cytogenetic analysis, chromosomal abnor-
malities, and prior therapy as appropriate. The series of 89
t-AML cases comprised 12 individuals (14%) with a docu-
mented history of myelodysplastic syndrome. The remaining
77 individuals presented without a preceding dysplastic phase.
The type of chromosomal abnormality and prevalence of
aberrations observed differed in t-AML from de novo AML;
abnormalities involving 11q23 or the loss of 5q or 7q were more
prevalent among t-AML patients, as was the occurrence of
three or more aberrations (Table 1).
Information on the nature of the primary condition was
available for 57 of 89 t-AML cases. Cytotoxic therapy was given
for primary malignancies in 50 of these 57 cases. Primary
malignancies included breast cancer (n 5 15), Hodgkin’s disease
(n 5 11), non-Hodgkin’s lymphoma (n 5 4), carcinoma of the
endometrium (n 5 3), acute lymphocytic leukemia (n 5 3),
malignant histiocytoma (n 5 2), prostate cancer (n 5 2), cervical
cancer (n 5 2), osteosarcoma (n 5 1), bladder cancer (n 5 1),
testicular cancer (n 5 1), rectal cancer (n 5 1), chronic lym-
phocytic leukemia (n 5 1), basal cell carcinoma (n 5 1), and lung
cancer (n 5 1). Before diagnosis of t-AML, one individual
received cytotoxic therapy for carcinoma of the endometrium 9
years before and non-Hodgkin’s lymphoma 5 years before. The
remaining 7 t-AML patients were treated with cytotoxic therapy
for nonmalignant conditions that included vasculitis (n 5 2),
thrombocytosis (n 5 2), tuberculosis (n 5 1), goiter (n 5 1), and
rheumatoid arthritis (n 5 1).
Among the 38 t-AML patients with previous exposure to
radiotherapy only (Table 1), the median latency period from
initial radiotherapy to diagnosis of AML was 72 months (based
on 23 cases with data available). Fifty-one t-AML patients had
previous exposure to chemotherapy and 19 of these had
previous exposure to both chemotherapy and radiotherapy;
the median latency period from initial chemotherapy to onset
of AML was 62.5 months (based on 38 cases with data
available). Among the 35 individuals for whom the usage of
specific chemotherapeutic agents was documented, the major-
ity (n 5 30) had prior exposure to combination chemotherapy,
for which alkylating agents were the most common compo-
nents used (Table 1).
GST Genotype and Risk of t-AML. Although the frequencies of
GSTM1 and GSTT1 null polymorphisms are elevated in the
t-AML patient series relative to the population controls, the risks
for both polymorphisms are equally raised among de novo AML
patients (Table 2), suggesting an increased risk of developing
acute myeloid leukemia per se (31). In contrast, individuals with
at least one GSTP1 Val allele (IleyVal or ValyVal) at codon 105
are significantly overrepresented among t-AML patients (63%)
but not among de novo AML patients (51%) compared with
population controls (51%), suggesting an increased risk of
developing t-AML specifically (OR 1.58, 95% CI 1.01–2.49)
(Table 2). Thus, individuals with at least one GSTP1 codon 105
Val allele are significantly overrepresented in the t-AML patient
series compared with de novo AML patients (OR 1.81, 95% CI
1.11–2.94) (Table 3).
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GST Genotype and Risk of t-AML by Type of Therapy. No association
with t-AML and either GSTM1 or GSTT1 by therapy type was
evident (Table 3). In contrast, the GSTP1 codon 105 Val allele
appears to confer a significantly increased risk of t-AML after
chemotherapy (OR 2.66, 95% CI 1.39–5.09), but not after
radiotherapy, compared with de novo AML (OR 1.01, 95% CI
0.50–2.07) (Table 3). Twenty-one of the 51 t-AML patients who
had prior chemotherapy were exposed to at least one confirmed
GSTP1 substrate, which is associated with an excess risk of
t-AML with presence of at least one Val allele at GSTP1 codon
105, compared with de novo AML patients (OR 4.34, 95% CI
1.43–13.20) (Table 4). However, a nonsignificant 2-fold in-
Table 1. Description of t-AML cases, de novo AML cases, and controls
Variable t-AML cases, n (%) De novo AML cases, n (%) Controls, n (%)
Total 89 (100) 420 (100) 1,022 (100)
Sex
Male 36 (40) 227 (54) 538 (53)
Female 53 (60) 193 (46) 484 (47)
Age, years
Mean (range) 55.3 (17.4–77.8) 47.5 (16.2–70.0) 48.6 (16.2–69.9)
Ethnic group
United Kingdom Caucasian 69 (78) 420 (100) 1,022 (100)
Not known 20 (22) — —
FAB Type*
M0 2 (2) 21 (5) —
M1 10 (11) 75 (18) —
M2 15 (17) 97 (23) —
M3 11 (12) 53 (13) —
M4 15 (17) 71 (17) —
M5 9 (10) 37 (9) —
M6 5 (6) 18 (4) —
M7 3 (3) 4 (1) —
Not known 19 (21) 44 (10) —
Cytogenetic investigation
Successful 68 (76) 341 (81) —
Failed 2 (2) 23 (5) —
Not done 19 (21) 56 (13) —
Chromosomal abnormalities†
No abnormality 22 (32) 149 (44) —
Any abnormality 46 (68) 192 (56) —
t(15;17)(q22;q12) 8 (12) 44 (13) —
t(8;21)(q22;q22) 0 (0) 26 (8) —
inv(16)(p13q22) 1 (1) 18 (5) —
Abnormality involving
11q23 8 (12) 12 (4) —
Loss of 5q 8 (12) 14 (4) —
Loss of 7q 19 (28) 26 (8) —
18 9 (13) 40 (12) —
Complex ($3
aberrations)
22 (32) 39 (11) —
Prior therapy
Radiotherapy only 38 (43) — —
Any chemotherapy‡ 51 (57) — —
Alkylating agents 24 (27) — —
Topoisomerase inhibitors 13 (15) — —
Antimetabolites 14 (16) — —
Tubulin inhibitors 13 (15) — —
Corticosteroids 15 (17) — —
Details not available 16 (18) — —
*French–American–British acute leukemia classification.
†Chromosomal abnormalities listed are the most common observed in AML and classification is not mutually
exclusive. Percentages are based on the number of patients for whom cytogenetic investigation was
successful.
‡Nineteen patients received both chemotherapy and radiotherapy. Alkylating agents: chlorambucil, dacar-
bazine, busulfan, mechlorethamine, procarbazine, ifosfamide, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
(CCNU), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), mitomycin C, any cisplatin derivative, melphalan, and
cyclophosphamide. Topoisomerase inhibitors: mitoxantrone, adriamycin (doxorubicin), etoposide, epirubi-
cin, idarubicin, and daunorubicin (bleomycin is also included in this group). Antimetabolites: methotrexate,
azathioprine, 5-fluorouracil, cytosine arabinonucleoside, and hydroxyurea. Tubulin inhibitors: vincristine
and vinblastine. Corticosteroids: prednisone and prednisolone (cyclosporin A is also included in this group).
Patients are listed more than once if they received more than one type of therapy.
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creased risk of t-AML was still present in persons previously
treated with other or unknown chemotherapeutic agents (OR
2.00, 95% CI 0.91–4.40) (Table 4).
Discussion
Our findings suggest that t-AML, but not de novo AML, is
associated with a polymorphism in the gene that encodes
GSTP1. Specifically, these data suggest that individuals either
heterozygous (IleyVal) or homozygous for Val at codon 105 of
GSTP1 were twice as likely as Ile homozygotes to develop
t-AML after chemotherapy (OR 2.66, 95% CI 1.39–5.09), and
greater than 4 times more likely if they had been exposed to a
known GSTP1 substrate (OR 4.34, 95% CI 1.43–13.20). A
statistically nonsignificant 2-fold increased risk of t-AML was
still observed when individuals were not exposed to a known
GSTP1 substrate, suggesting that there are other chemothera-
peutic agents yet to be confirmed as substrates. Unlike GSTP1,
the risks associated with GSTT1 and GSTM1 gene-deletion
polymorphisms appear no different for t-AML and de novo
AML, consistent with previous reports (15, 31, 47, 48).
The more frequent occurrence of abnormalities involving
11q23 or the loss of 5q or 7q among t-AML patients is consistent
Table 2. GST genotype and the risk of developing t-AML or de novo AML
Variable
Controls De novo AML* t-AML
n (%) n (%) OR 95% CI n (%) OR 95% CI
GSTM1†
Carriers 523 (51) 188 (45) 1 — 40 (45) 1 —
Null 496 (49) 229 (55) 1.28 1.02–1.61 49 (55) 1.31 0.84–2.03
SNA 3 3 0
GSTT1†
Carriers 879 (86) 338 (81) 1 — 70 (79) 1 —
Null 140 (14) 79 (19) 1.47 1.08–1.99 19 (21) 1.79 1.04–3.10
SNA 3 3 0
GSTP1‡
IleyIle 497 (49) 202 (49) 1 — 33 (37) 1 —
IleyVal 378 (37) 151 (36) 0.98 0.76–1.26 40 (45) 1.51 0.93–2.46
ValyVal 140 (14) 61 (15) 1.06 0.75–1.50 16 (18) 1.80 0.95–3.39
SNA 7 6 0
GSTP1‡
IleyIle 497 (49) 202 (49) 1 — 33 (37) 1 —
IleyVal 1 ValyVal 518 (51) 212 (51) 1.00 0.80–1.26 56 (63) 1.58 1.01–2.49
SNA 7 6 0
ORs and 95% CIs were estimated relative to controls for an unmatched analysis adjusted for age and sex. SNA, sample not amplifiable
or not available.
*A similar analysis using the majority of the patients and controls described in this study has been published previously (31).
†Carriers of at least one intact allele are used as reference.
‡Isoleucine homozygotes (IleyIle) are used as reference.
Table 3. GST genotype and the risk of developing t-AML by type of previous therapy
Variable
De novo AML
t-AML
n (%) Total t-AML cases Radiotherapy Chemotherapy
n (%) OR 95% CI n (%) OR 95% CI n (%) OR 95% CI
GSTM1*
Carriers 188 (45) 40 (45) 1 — 15 (39) 1 — 25 (49) 1 —
Null 229 (55) 49 (55) 0.99 0.62–1.60 23 (61) 1.25 0.61–2.60 26 (51) 0.85 0.48–1.53
SNA 3 0 0 0
GSTT1*
Carriers 338 (81) 70 (79) 1 — 33 (87) 1 — 37 (73) 1 —
Null 79 (19) 19 (21) 1.19 0.67–2.13 5 (13) 0.66 0.26–1.84 14 (27) 1.61 0.83–3.14
SNA 3 0 0 0
GSTP1†
IleyIle 202 (49) 33 (37) 1 — 19 (50) 1 — 14 (27) 1 —
IleyVal 151 (36) 40 (45) 1.87 1.11–3.17 12 (32) 0.94 0.42–2.12 28 (55) 2.87 1.45–5.67
ValyVal 61 (15) 16 (18) 1.67 0.84–3.30 7 (18) 1.16 0.43–3.13 9 (18) 2.17 0.89–5.29
SNA 6 0 0 0
GSTP1†
IleyIle 202 (49) 33 (37) 1 — 19 (50) 1 — 14 (27) 1 —
IleyVal 1 ValyVal 212 (51) 56 (63) 1.81 1.11–2.94 19 (50) 1.01 0.50–2.07 37 (73) 2.66 1.39–5.09
SNA 6 0 0 0
ORs and 95% CIs were estimated relative to de novo AML cases for an unmatched analysis adjusted for age and sex. SNA, sample not amplifiable.
*Carriers of at least one intact allele are used as reference.
†Isoleucine homozygotes (IleyIle) are used as reference.
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with prior exposure to DNA topoisomerase II inhibitors and
alkylating agents, respectively (11, 49). Other than the relatively
high percentage of patients with a t(15;17), the cytogenetic
profile of these t-AML patients is similar to those reported in
previous studies (11, 49, 50).
Five subjects had genetic alterations (assessed by cytogenetic
analysis) affecting the chromosomal sites of GSTM1, GSTT1, or
GSTP1. PCR was performed with genomic DNA extracted from
leukemic bone marrow in these five individuals. Thus, it is
possible that genotyping may be inaccurate because of loss of
genetic material. However, three of these subjects showed only
gains of genetic material at the involved sites, which is unlikely
to affect genotyping. Deletions affecting 11q13 (GSTP1) were
found in the remaining two individuals, both of whom were
genotyped as Ile homozygotes at codon 105. The statistical
significance of the results is not affected by assuming loss of a Val
allele during leukemogenesis in these subjects and therefore
considering them to be IleyVal heterozygotes at the GSTP1
codon 105 locus (data not shown). We also acknowledge the
hypothetical possibility that point mutation at the GSTP1 codon
105 locus during leukemic initiation and the subsequent selec-
tion of mutated clones during disease development may give rise
to inaccurate genotyping if leukemic bone marrow is used as a
source of DNA, as it is for some t-AML patients in this study.
However, we feel it is unlikely that GSTP1 mutations would be
selected during tumor initiation or progression because this gene
is neither a tumor suppressor nor a protooncogene. As such, we
feel that inaccurate genotyping does not represent a significant
problem in this study.
Forty-two of the 51 t-AML individuals with prior chemother-
apy exposure were confirmed as United Kingdom Caucasians.
The results of statistical analysis remained significant when
individuals of unknown ethnic origin were excluded (OR 3.47,
95% CI 1.60–7.50). Twenty of the 21 t-AML patients with prior
exposure to a known GSTP1 substrate were confirmed as United
Kingdom Caucasians. The results of statistical analysis remained
significant when the individual of unknown ethnic origin was
excluded (OR 4.09, 95% CI 1.34–12.54).
Our data support the hypothesis that the GSTP1 codon 105
polymorphism modulates the leukemogenic effect of certain
chemotherapeutic agents; this is consistent with prior observa-
tions showing that this polymorphism alters protein function.
Biochemical studies have demonstrated a lower thermal stability
of GSTP1 Val-105 compared with GSTP1 Ile-105 (24, 25) and
also lower conjugating activity in Val homozygotes compared
with Ile homozygotes, with heterozygotes displaying intermedi-
ate activity (51). In contrast, the data reported in this study are
not consistent with an allele dosage effect. When GSTP1 was
analyzed as a trichotamous variable, heterozygotes and Val
homozygotes appeared to have a similarly increased risk of
t-AML following chemotherapy (IleyVal, OR 2.87, 95% CI
1.45–5.67; ValyVal, OR 2.17, 95% CI 0.89–5.29), which suggests
a threshold effect rather than a dosage effect for t-AML
susceptibility. However, the small number of Val homozygotes
limits the interpretation of these data in this respect.
Individuals with at least one Val allele at codon 105 of GSTP1
may have an underlying predisposition to cancers when exposure
to environmentally derived or endogenously formed GSTP1
substrates is a risk factor (29). However, acute leukemia appears
not to be one of these cancers because GSTP1 codon 105 status
is not a risk factor for de novo AML (31) (Table 2), providing
evidence that the increased susceptibility to t-AML suggested in
our study is specific to prior therapeutic exposure.
It remains possible that the population at risk of t-AML may
be genetically biased because of a role for the GSTP1 codon 105
polymorphism in modulating either susceptibility to primary
cancer or survival after therapy. Indeed, the GSTP1 codon 105
Val allele has been reported to be associated with a significantly
increased risk of bladder and testicular cancer (29), and with a
nonsignificantly increased risk of breast cancer (52). However, a
similar distribution in GSTP1 codon 105 genotype in healthy
controls and t-AML patients with prior exposure to radiotherapy
suggests that predisposition to primary cancer does not result in
significant population bias. Individuals with Val at GSTP1 codon
105 may respond better to chemotherapy given for their primary
cancer because of lower GSTP1 activity and increased chemo-
therapy-induced cytotoxicity in target tumor tissue. Indeed,
codon 105 Val homozygotes have a significantly better prognosis
than codon 105 Ile homozygotes treated with cyclophosphamide
and adriamycin (both GSTP1 substrates) for breast cancer (53).
Improved prognosis and long-term survival after therapy would
increase the prevalence of individuals with Val at codon 105 in
the population at risk of t-AML, although, unfortunately, we are
presently unable to determine the potential effect on our results.
Bone marrow is particularly sensitive to the toxic effects of
chemotherapeutic alkylating agents, which include cyclophosph-
amide, chlorambucil, busulfan, and ifosfamide, among others
(54). The reasons for this remain unclear, although low DNA
repair activity and lack of GST a expression in bone marrow
CD341 cells have been implicated (55, 56). Toxicity manifests
Table 4. Comparison of t-AML cases previously treated with chemotherapy and de novo AML cases, by exposure
to confirmed GSTP1 substrates or other chemotherapeutic agents and by genotype for GSTP1
Variable
De novo AML
t-AML
Known GSTP1 substrate* Other or unknown chemotherapeutic agents
n (%) n (%) OR 95% CI n (%) OR 95% CI
GSTP1†
IleyIle 202 (49) 4 (19) 1 — 10 (33) 1 —
IleyVal 151 (36) 12 (57) 4.43 1.39–14.12 16 (53) 2.26 0.99–5.15
ValyVal 61 (15) 5 (24) 4.16 1.07–16.07 4 (13) 1.38 0.42–4.56
SNA 6 0 0
GSTP1†
IleyIle 202 (49) 4 (19) 1 — 10 (33) 1 —
IleyVal 1 ValyVal 212 (51) 17 (81) 4.34 1.43–13.20 20 (67) 2.00 0.91–4.40
SNA 6 0 0
ORs and 95% CIs were estimated relative to de novo AML cases for an unmatched analysis adjusted for age and sex. SNA, sample not
amplifiable.
*Etoposide, chlorambucil, adriamycin, melphalan, cyclophosphamide, busulfan, ifosfamide, and any cisplatin derivative.
†Isoleucine homozygotes (IleyIle) are used as reference.
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clinically as pancytopenia, and it is dose-limiting for several
chemotherapeutic alkylating agents. One approach to overcome
acute toxicity is to artificially protect the bone marrow by using
gene transfer techniques. Presumably this approach would also
protect against mutagenesis and reduce the risk of t-AML. Use
of GSTP1 as the transgene has proven successful in protecting
human bone marrow stem cells and bone marrow in animal
models against the toxic effects of chemotherapeutic alkylating
agents (37–39). Our results highlight the importance of selecting
the appropriate transgene variant to confer maximum protection
and suggest codon 105 as a residue that may be artificially
mutated to potentially generate variants with even higher cata-
lytic activity.
In conclusion, our data suggest that individuals with at least
one GSTP1 codon 105 Val allele are at a significantly increased
risk of developing t-AML, compared with Ile homozygotes, after
exposure to such chemotherapeutics as cyclophosphamide,
chlorambucil, adriamycin, etoposide, and cisplatin derivatives.
These agents form the backbone of chemotherapeutic regimes
for the treatment of numerous malignancies, including lym-
phatic, bladder, breast, ovarian, lung, and testicular cancer. If
GSTP1 codon 105 status can identify individuals at high risk of
developing a second therapy-related cancer, then it may be
possible to tailor chemotherapy to minimize leukemogenic
potential. Of course, the primary aim of any cancer therapeutic
regime is to cure the patient of the disease. However, with high
cure frequency and long-term survival after treatment for such
cancers as pediatric Hodgkin’s disease (57) and pediatric acute
lymphocytic leukemia (58), the threat of t-AML in later life must
be considered. GSTP1 codon 105 status may also be used to
identify patients who may benefit from more intensive surveil-
lance for t-AML after chemotherapy.
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